Global Fast-Acting Insulin Analog Market Growth 2022-2028
The global market for Fast-Acting Insulin Analog is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Fast-Acting Insulin Analog market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Fast-Acting Insulin Analog market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Fast-Acting Insulin Analog market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Fast-Acting Insulin Analog market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Fast-Acting Insulin Analog players cover Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals and The United Laboratories International Holdings and etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Fast-Acting Insulin Analog market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Fast-Acting Insulin Analog market, with both quantitative and qualitative data, to help readers understand how the Fast-Acting Insulin Analog market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Fast-Acting Insulin Analog market and forecasts the market size by Type (Insulin Aspart, Insulin Lispro and Insulin Glulisine), by Application (Type 2 Diabetes, Type 1 Diabetes, Gestational Diabetes and Other Diabetes), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Insulin Aspart
Insulin Lispro
Insulin Glulisine
Segmentation by application
Type 2 Diabetes
Type 1 Diabetes
Gestational Diabetes
Other Diabetes
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
Novo Nordisk
Sanofi
Eli Lilly and Company
Gan and Lee Pharmaceuticals
The United Laboratories International Holdings
Tonghua Dongbao Pharmaceutical
Chapter Introduction
Chapter 1: Scope of Fast-Acting Insulin Analog, Research Methodology, etc.
Chapter 2: Executive Summary, global Fast-Acting Insulin Analog market size (sales and revenue) and CAGR, Fast-Acting Insulin Analog market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Fast-Acting Insulin Analog sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Fast-Acting Insulin Analog sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Fast-Acting Insulin Analog market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings and Tonghua Dongbao Pharmaceutical, etc.
Chapter 14: Research Findings and Conclusion
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Fast-Acting Insulin Analog Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Fast-Acting Insulin Analog by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Fast-Acting Insulin Analog by Country/Region, 2017, 2022 & 2028
2.2 Fast-Acting Insulin Analog Segment by Type
2.2.1 Insulin Aspart
2.2.2 Insulin Lispro
2.2.3 Insulin Glulisine
2.3 Fast-Acting Insulin Analog Sales by Type
2.3.1 Global Fast-Acting Insulin Analog Sales Market Share by Type (2017-2022)
2.3.2 Global Fast-Acting Insulin Analog Revenue and Market Share by Type (2017-2022)
2.3.3 Global Fast-Acting Insulin Analog Sale Price by Type (2017-2022)
2.4 Fast-Acting Insulin Analog Segment by Application
2.4.1 Type 2 Diabetes
2.4.2 Type 1 Diabetes
2.4.3 Gestational Diabetes
2.4.4 Other Diabetes
2.5 Fast-Acting Insulin Analog Sales by Application
2.5.1 Global Fast-Acting Insulin Analog Sale Market Share by Application (2017-2022)
2.5.2 Global Fast-Acting Insulin Analog Revenue and Market Share by Application (2017-2022)
2.5.3 Global Fast-Acting Insulin Analog Sale Price by Application (2017-2022)
3 Global Fast-Acting Insulin Analog by Company
3.1 Global Fast-Acting Insulin Analog Breakdown Data by Company
3.1.1 Global Fast-Acting Insulin Analog Annual Sales by Company (2020-2022)
3.1.2 Global Fast-Acting Insulin Analog Sales Market Share by Company (2020-2022)
3.2 Global Fast-Acting Insulin Analog Annual Revenue by Company (2020-2022)
3.2.1 Global Fast-Acting Insulin Analog Revenue by Company (2020-2022)
3.2.2 Global Fast-Acting Insulin Analog Revenue Market Share by Company (2020-2022)
3.3 Global Fast-Acting Insulin Analog Sale Price by Company
3.4 Key Manufacturers Fast-Acting Insulin Analog Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Fast-Acting Insulin Analog Product Location Distribution
3.4.2 Players Fast-Acting Insulin Analog Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Fast-Acting Insulin Analog by Geographic Region
4.1 World Historic Fast-Acting Insulin Analog Market Size by Geographic Region (2017-2022)
4.1.1 Global Fast-Acting Insulin Analog Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Fast-Acting Insulin Analog Annual Revenue by Geographic Region
4.2 World Historic Fast-Acting Insulin Analog Market Size by Country/Region (2017-2022)
4.2.1 Global Fast-Acting Insulin Analog Annual Sales by Country/Region (2017-2022)
4.2.2 Global Fast-Acting Insulin Analog Annual Revenue by Country/Region
4.3 Americas Fast-Acting Insulin Analog Sales Growth
4.4 APAC Fast-Acting Insulin Analog Sales Growth
4.5 Europe Fast-Acting Insulin Analog Sales Growth
4.6 Middle East & Africa Fast-Acting Insulin Analog Sales Growth
5 Americas
5.1 Americas Fast-Acting Insulin Analog Sales by Country
5.1.1 Americas Fast-Acting Insulin Analog Sales by Country (2017-2022)
5.1.2 Americas Fast-Acting Insulin Analog Revenue by Country (2017-2022)
5.2 Americas Fast-Acting Insulin Analog Sales by Type
5.3 Americas Fast-Acting Insulin Analog Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Fast-Acting Insulin Analog Sales by Region
6.1.1 APAC Fast-Acting Insulin Analog Sales by Region (2017-2022)
6.1.2 APAC Fast-Acting Insulin Analog Revenue by Region (2017-2022)
6.2 APAC Fast-Acting Insulin Analog Sales by Type
6.3 APAC Fast-Acting Insulin Analog Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Fast-Acting Insulin Analog by Country
7.1.1 Europe Fast-Acting Insulin Analog Sales by Country (2017-2022)
7.1.2 Europe Fast-Acting Insulin Analog Revenue by Country (2017-2022)
7.2 Europe Fast-Acting Insulin Analog Sales by Type
7.3 Europe Fast-Acting Insulin Analog Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Fast-Acting Insulin Analog by Country
8.1.1 Middle East & Africa Fast-Acting Insulin Analog Sales by Country (2017-2022)
8.1.2 Middle East & Africa Fast-Acting Insulin Analog Revenue by Country (2017-2022)
8.2 Middle East & Africa Fast-Acting Insulin Analog Sales by Type
8.3 Middle East & Africa Fast-Acting Insulin Analog Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Fast-Acting Insulin Analog
10.3 Manufacturing Process Analysis of Fast-Acting Insulin Analog
10.4 Industry Chain Structure of Fast-Acting Insulin Analog
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Fast-Acting Insulin Analog Distributors
11.3 Fast-Acting Insulin Analog Customer
12 World Forecast Review for Fast-Acting Insulin Analog by Geographic Region
12.1 Global Fast-Acting Insulin Analog Market Size Forecast by Region
12.1.1 Global Fast-Acting Insulin Analog Forecast by Region (2023-2028)
12.1.2 Global Fast-Acting Insulin Analog Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Fast-Acting Insulin Analog Forecast by Type
12.7 Global Fast-Acting Insulin Analog Forecast by Application
13 Key Players Analysis
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Fast-Acting Insulin Analog Product Offered
13.1.3 Novo Nordisk Fast-Acting Insulin Analog Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Fast-Acting Insulin Analog Product Offered
13.2.3 Sanofi Fast-Acting Insulin Analog Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 Eli Lilly and Company
13.3.1 Eli Lilly and Company Company Information
13.3.2 Eli Lilly and Company Fast-Acting Insulin Analog Product Offered
13.3.3 Eli Lilly and Company Fast-Acting Insulin Analog Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Eli Lilly and Company Main Business Overview
13.3.5 Eli Lilly and Company Latest Developments
13.4 Gan and Lee Pharmaceuticals
13.4.1 Gan and Lee Pharmaceuticals Company Information
13.4.2 Gan and Lee Pharmaceuticals Fast-Acting Insulin Analog Product Offered
13.4.3 Gan and Lee Pharmaceuticals Fast-Acting Insulin Analog Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Gan and Lee Pharmaceuticals Main Business Overview
13.4.5 Gan and Lee Pharmaceuticals Latest Developments
13.5 The United Laboratories International Holdings
13.5.1 The United Laboratories International Holdings Company Information
13.5.2 The United Laboratories International Holdings Fast-Acting Insulin Analog Product Offered
13.5.3 The United Laboratories International Holdings Fast-Acting Insulin Analog Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 The United Laboratories International Holdings Main Business Overview
13.5.5 The United Laboratories International Holdings Latest Developments
13.6 Tonghua Dongbao Pharmaceutical
13.6.1 Tonghua Dongbao Pharmaceutical Company Information
13.6.2 Tonghua Dongbao Pharmaceutical Fast-Acting Insulin Analog Product Offered
13.6.3 Tonghua Dongbao Pharmaceutical Fast-Acting Insulin Analog Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Tonghua Dongbao Pharmaceutical Main Business Overview
13.6.5 Tonghua Dongbao Pharmaceutical Latest Developments
14 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Fast-Acting Insulin Analog Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Fast-Acting Insulin Analog Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Insulin Aspart
Table 4. Major Players of Insulin Lispro
Table 5. Major Players of Insulin Glulisine
Table 6. Global Fast-Acting Insulin Analog Sales by Type (2017-2022) & (K Units)
Table 7. Global Fast-Acting Insulin Analog Sales Market Share by Type (2017-2022)
Table 8. Global Fast-Acting Insulin Analog Revenue by Type (2017-2022) & ($ million)
Table 9. Global Fast-Acting Insulin Analog Revenue Market Share by Type (2017-2022)
Table 10. Global Fast-Acting Insulin Analog Sale Price by Type (2017-2022) & (US$/Unit)
Table 11. Global Fast-Acting Insulin Analog Sales by Application (2017-2022) & (K Units)
Table 12. Global Fast-Acting Insulin Analog Sales Market Share by Application (2017-2022)
Table 13. Global Fast-Acting Insulin Analog Revenue by Application (2017-2022)
Table 14. Global Fast-Acting Insulin Analog Revenue Market Share by Application (2017-2022)
Table 15. Global Fast-Acting Insulin Analog Sale Price by Application (2017-2022) & (US$/Unit)
Table 16. Global Fast-Acting Insulin Analog Sales by Company (2020-2022) & (K Units)
Table 17. Global Fast-Acting Insulin Analog Sales Market Share by Company (2020-2022)
Table 18. Global Fast-Acting Insulin Analog Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Fast-Acting Insulin Analog Revenue Market Share by Company (2020-2022)
Table 20. Global Fast-Acting Insulin Analog Sale Price by Company (2020-2022) & (US$/Unit)
Table 21. Key Manufacturers Fast-Acting Insulin Analog Producing Area Distribution and Sales Area
Table 22. Players Fast-Acting Insulin Analog Products Offered
Table 23. Fast-Acting Insulin Analog Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Fast-Acting Insulin Analog Sales by Geographic Region (2017-2022) & (K Units)
Table 27. Global Fast-Acting Insulin Analog Sales Market Share Geographic Region (2017-2022)
Table 28. Global Fast-Acting Insulin Analog Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Fast-Acting Insulin Analog Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Fast-Acting Insulin Analog Sales by Country/Region (2017-2022) & (K Units)
Table 31. Global Fast-Acting Insulin Analog Sales Market Share by Country/Region (2017-2022)
Table 32. Global Fast-Acting Insulin Analog Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Fast-Acting Insulin Analog Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Fast-Acting Insulin Analog Sales by Country (2017-2022) & (K Units)
Table 35. Americas Fast-Acting Insulin Analog Sales Market Share by Country (2017-2022)
Table 36. Americas Fast-Acting Insulin Analog Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Fast-Acting Insulin Analog Revenue Market Share by Country (2017-2022)
Table 38. Americas Fast-Acting Insulin Analog Sales by Type (2017-2022) & (K Units)
Table 39. Americas Fast-Acting Insulin Analog Sales Market Share by Type (2017-2022)
Table 40. Americas Fast-Acting Insulin Analog Sales by Application (2017-2022) & (K Units)
Table 41. Americas Fast-Acting Insulin Analog Sales Market Share by Application (2017-2022)
Table 42. APAC Fast-Acting Insulin Analog Sales by Region (2017-2022) & (K Units)
Table 43. APAC Fast-Acting Insulin Analog Sales Market Share by Region (2017-2022)
Table 44. APAC Fast-Acting Insulin Analog Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Fast-Acting Insulin Analog Revenue Market Share by Region (2017-2022)
Table 46. APAC Fast-Acting Insulin Analog Sales by Type (2017-2022) & (K Units)
Table 47. APAC Fast-Acting Insulin Analog Sales Market Share by Type (2017-2022)
Table 48. APAC Fast-Acting Insulin Analog Sales by Application (2017-2022) & (K Units)
Table 49. APAC Fast-Acting Insulin Analog Sales Market Share by Application (2017-2022)
Table 50. Europe Fast-Acting Insulin Analog Sales by Country (2017-2022) & (K Units)
Table 51. Europe Fast-Acting Insulin Analog Sales Market Share by Country (2017-2022)
Table 52. Europe Fast-Acting Insulin Analog Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Fast-Acting Insulin Analog Revenue Market Share by Country (2017-2022)
Table 54. Europe Fast-Acting Insulin Analog Sales by Type (2017-2022) & (K Units)
Table 55. Europe Fast-Acting Insulin Analog Sales Market Share by Type (2017-2022)
Table 56. Europe Fast-Acting Insulin Analog Sales by Application (2017-2022) & (K Units)
Table 57. Europe Fast-Acting Insulin Analog Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Fast-Acting Insulin Analog Sales by Country (2017-2022) & (K Units)
Table 59. Middle East & Africa Fast-Acting Insulin Analog Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Fast-Acting Insulin Analog Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Fast-Acting Insulin Analog Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Fast-Acting Insulin Analog Sales by Type (2017-2022) & (K Units)
Table 63. Middle East & Africa Fast-Acting Insulin Analog Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Fast-Acting Insulin Analog Sales by Application (2017-2022) & (K Units)
Table 65. Middle East & Africa Fast-Acting Insulin Analog Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Fast-Acting Insulin Analog
Table 67. Key Market Challenges & Risks of Fast-Acting Insulin Analog
Table 68. Key Industry Trends of Fast-Acting Insulin Analog
Table 69. Fast-Acting Insulin Analog Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Fast-Acting Insulin Analog Distributors List
Table 72. Fast-Acting Insulin Analog Customer List
Table 73. Global Fast-Acting Insulin Analog Sales Forecast by Region (2023-2028) & (K Units)
Table 74. Global Fast-Acting Insulin Analog Sales Market Forecast by Region
Table 75. Global Fast-Acting Insulin Analog Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Fast-Acting Insulin Analog Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Fast-Acting Insulin Analog Sales Forecast by Country (2023-2028) & (K Units)
Table 78. Americas Fast-Acting Insulin Analog Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Fast-Acting Insulin Analog Sales Forecast by Region (2023-2028) & (K Units)
Table 80. APAC Fast-Acting Insulin Analog Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Fast-Acting Insulin Analog Sales Forecast by Country (2023-2028) & (K Units)
Table 82. Europe Fast-Acting Insulin Analog Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Fast-Acting Insulin Analog Sales Forecast by Country (2023-2028) & (K Units)
Table 84. Middle East & Africa Fast-Acting Insulin Analog Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Fast-Acting Insulin Analog Sales Forecast by Type (2023-2028) & (K Units)
Table 86. Global Fast-Acting Insulin Analog Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Fast-Acting Insulin Analog Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Fast-Acting Insulin Analog Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Fast-Acting Insulin Analog Sales Forecast by Application (2023-2028) & (K Units)
Table 90. Global Fast-Acting Insulin Analog Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Fast-Acting Insulin Analog Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Fast-Acting Insulin Analog Revenue Market Share Forecast by Application (2023-2028)
Table 93. Novo Nordisk Basic Information, Fast-Acting Insulin Analog Manufacturing Base, Sales Area and Its Competitors
Table 94. Novo Nordisk Fast-Acting Insulin Analog Product Offered
Table 95. Novo Nordisk Fast-Acting Insulin Analog Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 96. Novo Nordisk Main Business
Table 97. Novo Nordisk Latest Developments
Table 98. Sanofi Basic Information, Fast-Acting Insulin Analog Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi Fast-Acting Insulin Analog Product Offered
Table 100. Sanofi Fast-Acting Insulin Analog Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 101. Sanofi Main Business
Table 102. Sanofi Latest Developments
Table 103. Eli Lilly and Company Basic Information, Fast-Acting Insulin Analog Manufacturing Base, Sales Area and Its Competitors
Table 104. Eli Lilly and Company Fast-Acting Insulin Analog Product Offered
Table 105. Eli Lilly and Company Fast-Acting Insulin Analog Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 106. Eli Lilly and Company Main Business
Table 107. Eli Lilly and Company Latest Developments
Table 108. Gan and Lee Pharmaceuticals Basic Information, Fast-Acting Insulin Analog Manufacturing Base, Sales Area and Its Competitors
Table 109. Gan and Lee Pharmaceuticals Fast-Acting Insulin Analog Product Offered
Table 110. Gan and Lee Pharmaceuticals Fast-Acting Insulin Analog Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 111. Gan and Lee Pharmaceuticals Main Business
Table 112. Gan and Lee Pharmaceuticals Latest Developments
Table 113. The United Laboratories International Holdings Basic Information, Fast-Acting Insulin Analog Manufacturing Base, Sales Area and Its Competitors
Table 114. The United Laboratories International Holdings Fast-Acting Insulin Analog Product Offered
Table 115. The United Laboratories International Holdings Fast-Acting Insulin Analog Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 116. The United Laboratories International Holdings Main Business
Table 117. The United Laboratories International Holdings Latest Developments
Table 118. Tonghua Dongbao Pharmaceutical Basic Information, Fast-Acting Insulin Analog Manufacturing Base, Sales Area and Its Competitors
Table 119. Tonghua Dongbao Pharmaceutical Fast-Acting Insulin Analog Product Offered
Table 120. Tonghua Dongbao Pharmaceutical Fast-Acting Insulin Analog Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 121. Tonghua Dongbao Pharmaceutical Main Business
Table 122. Tonghua Dongbao Pharmaceutical Latest Developments
List of Figures
Figure 1. Picture of Fast-Acting Insulin Analog
Figure 2. Fast-Acting Insulin Analog Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Fast-Acting Insulin Analog Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Fast-Acting Insulin Analog Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Fast-Acting Insulin Analog Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Insulin Aspart
Figure 10. Product Picture of Insulin Lispro
Figure 11. Product Picture of Insulin Glulisine
Figure 12. Global Fast-Acting Insulin Analog Sales Market Share by Type in 2021
Figure 13. Global Fast-Acting Insulin Analog Revenue Market Share by Type (2017-2022)
Figure 14. Fast-Acting Insulin Analog Consumed in Type 2 Diabetes
Figure 15. Global Fast-Acting Insulin Analog Market: Type 2 Diabetes (2017-2022) & (K Units)
Figure 16. Fast-Acting Insulin Analog Consumed in Type 1 Diabetes
Figure 17. Global Fast-Acting Insulin Analog Market: Type 1 Diabetes (2017-2022) & (K Units)
Figure 18. Fast-Acting Insulin Analog Consumed in Gestational Diabetes
Figure 19. Global Fast-Acting Insulin Analog Market: Gestational Diabetes (2017-2022) & (K Units)
Figure 20. Fast-Acting Insulin Analog Consumed in Other Diabetes
Figure 21. Global Fast-Acting Insulin Analog Market: Other Diabetes (2017-2022) & (K Units)
Figure 22. Global Fast-Acting Insulin Analog Sales Market Share by Application (2017-2022)
Figure 23. Global Fast-Acting Insulin Analog Revenue Market Share by Application in 2021
Figure 24. Fast-Acting Insulin Analog Revenue Market by Company in 2021 ($ Million)
Figure 25. Global Fast-Acting Insulin Analog Revenue Market Share by Company in 2021
Figure 26. Global Fast-Acting Insulin Analog Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global Fast-Acting Insulin Analog Revenue Market Share by Geographic Region in 2021
Figure 28. Global Fast-Acting Insulin Analog Sales Market Share by Region (2017-2022)
Figure 29. Global Fast-Acting Insulin Analog Revenue Market Share by Country/Region in 2021
Figure 30. Americas Fast-Acting Insulin Analog Sales 2017-2022 (K Units)
Figure 31. Americas Fast-Acting Insulin Analog Revenue 2017-2022 ($ Millions)
Figure 32. APAC Fast-Acting Insulin Analog Sales 2017-2022 (K Units)
Figure 33. APAC Fast-Acting Insulin Analog Revenue 2017-2022 ($ Millions)
Figure 34. Europe Fast-Acting Insulin Analog Sales 2017-2022 (K Units)
Figure 35. Europe Fast-Acting Insulin Analog Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa Fast-Acting Insulin Analog Sales 2017-2022 (K Units)
Figure 37. Middle East & Africa Fast-Acting Insulin Analog Revenue 2017-2022 ($ Millions)
Figure 38. Americas Fast-Acting Insulin Analog Sales Market Share by Country in 2021
Figure 39. Americas Fast-Acting Insulin Analog Revenue Market Share by Country in 2021
Figure 40. United States Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC Fast-Acting Insulin Analog Sales Market Share by Region in 2021
Figure 45. APAC Fast-Acting Insulin Analog Revenue Market Share by Regions in 2021
Figure 46. China Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 50. India Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe Fast-Acting Insulin Analog Sales Market Share by Country in 2021
Figure 53. Europe Fast-Acting Insulin Analog Revenue Market Share by Country in 2021
Figure 54. Germany Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 55. France Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa Fast-Acting Insulin Analog Sales Market Share by Country in 2021
Figure 60. Middle East & Africa Fast-Acting Insulin Analog Revenue Market Share by Country in 2021
Figure 61. Egypt Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country Fast-Acting Insulin Analog Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of Fast-Acting Insulin Analog in 2021
Figure 67. Manufacturing Process Analysis of Fast-Acting Insulin Analog
Figure 68. Industry Chain Structure of Fast-Acting Insulin Analog
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets